Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Accelerate Diagnostics reports Q1 losses but shows growth potential

Accelerate Diagnostics showcased growth potential with customer acquisitions, Wave program progress, and strategic partnerships, despite facing cost management challenges.
The company's focus on innovation, customer engagement, and operational efficiency positions it for market expansion and technology advancement in the diagnostics sector.
Addressing expense control, successful commercialization of new programs, and sustaining growth momentum are key focus areas for Accelerate Diagnostics to drive profitability.

Accelerate Diagnostics reports Q3 milestones amidst financial challenges

Accelerate Diagnostics demonstrated financial performance with notable milestones achieved in Q3 2024.
While facing challenges in managing cash burn and addressing analyst inquiries, the company showcased strengths in commercial progress and innovation.
Opportunities for growth and market leadership exist through leveraging recent FDA clearances and expanding into new markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics

Bruker

Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz. , Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification.

Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®

Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Albert Hu - Craig-Hallum Operator Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Third Quarter Results Conference Call. All participant's will be in listen-only mode.

Accelerate Diagnostics, Inc. (AXDX) Q3 2023 Earnings Call Transcript

TUCSON, Ariz. , Nov. 9, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023.

Accelerate Diagnostics Reports Third Quarter 2023 Results

TUCSON, Ariz. , Oct. 30, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30 p.m.

Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.

Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2023 Earnings Conference Call August 10, 2023 4:00 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - CEO, President & Director David Patience - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Conner Chamberlain - Craig-Hallum Dustin Scaringe - William Blair & Company Operator Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Q2 Results Conference Call. [Operator Instructions].

Accelerate Diagnostics, Inc. (AXDX) Q2 2023 Earnings Call Transcript

TUCSON, Ariz. , Aug. 10, 2023 /PRNewswire/ --  Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023.

Accelerate Diagnostics Reports Second Quarter 2023 Financial Results

TUCSON, Ariz. , July 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m.

Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results

TUCSON, Ariz. , July 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) (the "Company") a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.

Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split

Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?

TUCSON, Ariz. , June 13, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support agreement.

Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave

Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Incorporated 2023 Q1 Results Conference Call. All participants will be in listen-only mode.

Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript

TUCSON, Ariz. , May 11, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023.

Accelerate Diagnostics Reports First Quarter 2023 Financial Results

TUCSON, Ariz. , April 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m.

Accelerate Diagnostics scheduled call to review 2023 first quarter results

Accelerate Diagnostics (AXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Laura Pierson - IR Jack Phillips - President and CEO Steve Reichling - outgoing-CFO David Patience - incoming-CFO Conference Call Participants Alex Nowak - Craig-Hallum Dustin Scaringe - William Blair Operator Good afternoon, and welcome to the Accelerate Diagnostics Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Accelerate Diagnostics, Inc. (AXDX) Q4 2022 Earnings Call Transcript

TUCSON, Ariz. , March 29, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.

Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results

TUCSON, Ariz. , March 15, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m.

Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results

TUCSON, Ariz. , March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023.

Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement

TUCSON, Ariz. , March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023.

Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

TUCSON, Ariz. , Dec. 19, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit.

Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit

Boston, Massachusetts--(Newsfile Corp. - November 15, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have lost money in their Accelerate Diagnostics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/axdx.What is this all about?After the market closed on October 21, 2022, Accelerate Diagnostics, Inc. disclosed receiving a request from the U.S.

Accelerate Diagnostics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

News for Accelerate Diagnostics Stock (AXDX)